Application of raloxifene and oxaliplatin combined medicine in preparation of medicine for treating gastric cancer

A technology of combined medicine and gastric cancer, applied in the field of medicine

Inactive Publication Date: 2021-03-02
阿耳法猫(杭州)人工智能生物科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are no reports on the effect of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of raloxifene and oxaliplatin combined medicine in preparation of medicine for treating gastric cancer
  • Application of raloxifene and oxaliplatin combined medicine in preparation of medicine for treating gastric cancer
  • Application of raloxifene and oxaliplatin combined medicine in preparation of medicine for treating gastric cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 MTT method to detect the sensitivity of different gastric cancer cells to raloxifene

[0024] 1. Experimental materials

[0025] (1) Drugs: Raloxifene hydrochloride is commonly used clinically. In this example, raloxifene hydrochloride was used as the experimental drug.

[0026] The chemical structural formula of raloxifene hydrochloride is as follows:

[0027]

[0028] (2) Gastric cancer cells: human gastric cancer cells AGS and MGC803.

[0029] (3) Commercially available MTT kits.

[0030] 2. Experimental grouping

[0031] (1) Control group: blank control, that is, gastric cancer cells were not treated with any drugs.

[0032] (2) Experimental group: Gastric cancer cells were treated with different concentrations of raloxifene hydrochloride.

[0033] 3. MTT method to detect the sensitivity of different tumor cells to raloxifene

[0034] (1) Human gastric cancer cells AGS and MGC803 were inoculated into a 96-well plate at a rate of 5000-9000 cells pe...

Embodiment 2

[0036] Example 2 The effect of oxaliplatin alone or in combination with raloxifene and oxaliplatin on the inhibition rate of gastric cancer cells

[0037] 1. Experimental materials

[0038] (1) Drugs: raloxifene hydrochloride, oxaliplatin.

[0039] (2) Gastric cancer cells: human gastric cancer cells AGS and MGC803.

[0040] (3) Commercially available MTT kits.

[0041] 2. Experimental grouping

[0042] (1) Control group: Gastric cancer cells were only treated with oxaliplatin.

[0043] (2) Experimental group: Different concentrations of raloxifene hydrochloride and oxaliplatin were used in combination to treat gastric cancer cells.

[0044] 3. MTT method to detect the sensitivity of gastric cancer cells to the combination of raloxifene and oxaliplatin

[0045] (1) Human gastric cancer cells AGS and MGC803 were inoculated into 96-well plates at the number of 5000-9000 cells per well. After the cells adhered to the wall, different ratios of raloxifene hydrochloride and oxa...

Embodiment 3

[0047] Example 3 The effect of oxaliplatin alone or in combination with raloxifene and oxaliplatin on the inhibition rate of human gastric cancer tissue organoids

[0048] 1. Experimental materials

[0049] (1) Drugs: raloxifene hydrochloride, oxaliplatin.

[0050] (2) Gastric cancer cells: human gastric cancer tissue organoids.

[0051] (3) Commercially available CellTiter-Glo 3D kit.

[0052] 2. Experimental grouping

[0053] (1) Control group: only treated with oxaliplatin.

[0054] (2) Experimental group: Different concentrations of raloxifene hydrochloride and oxaliplatin were used in combination to treat human gastric cancer tissue organoids.

[0055] 3. Sensitivity of human gastric cancer tissue organoids to the combination of raloxifene and oxaliplatin

[0056] (1) Mix the treated human gastric cancer cells with Matrigel matrigel, add 50 μl of mixed Mtrigel matrigel to each well on a 48-well plate, add 250 μl complete medium to each well after gel formation, and p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicine, and particularly relates to an application of raloxifene and oxaliplatin combined medicine in preparation of a medicine for treating gastric cancer. Theapplication of the raloxifene and oxaliplatin combined medicine in preparation of the medicine for treating gastric cancer is proposed for the first time, raloxifene and oxaliplatin have an obvious synergistic effect, the curative effect is effectively improved, the curative effect is more remarkable compared with that of single components, and the lethality to tumor cells is improved; and the dosage is effectively reduced, so that the toxic and side effects are reduced. The combined use of raloxifene and oxaliplatin can save the cost, reduce the economic burden of patients, provide a new wayfor the prevention and treatment of gastric cancer, and have broad application prospects in the field of medicine and pharmacology.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to the application of raloxifene combined with oxaliplatin in the preparation of drugs for treating gastric cancer. Background technique [0002] Gastric cancer is a common malignant tumor of the digestive tract, ranking third in cancer-related deaths worldwide, and is one of the major health burdens of society. In China, gastric cancer is the second most prevalent cancer and the second leading cause of cancer death. Therefore, the development of anti-gastric cancer drugs is a hot spot of anti-tumor research and development in my country. Chemotherapy is currently the main treatment for gastric cancer, but the curative effect of chemotherapy alone is not good, and the median survival time is only 8-13 months. [0003] Oxaliplatin is the third-generation platinum anticancer drug after cisplatin and carboplatin. It has the characteristics of good anticancer effect and wide indications. It is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/555A61K31/4535A61P35/00
CPCA61K31/4535A61K31/555A61P35/00A61K2300/00
Inventor 李斌
Owner 阿耳法猫(杭州)人工智能生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap